MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202611074558 A) filed by Aanchal Khanna; Preet M. S. Bedi; Anurag Varshney; and Shruti Varshney on June 16, 2026, for Novel Coumarin-Vanillin Triazole Hybrids As Potent Antibacterial Agents Targeting Bacterial Topoisomerases.
Inventors include Aanchal Khanna; Preet M. S. Bedi; Anurag Varshney; and Shruti Varshney.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: The present invention relates to the field of medicinal chemistry, oncology, and pharmaceutical sciences, and discloses novel erlotinib-coumarin hybrid compounds linked via a 1,2,3-triazole moiety for targeted cancer therapy. The invention provides structurally engineered conjugates comprising an erlotinib-derived pharmacophore covalently attached to a coumarin scaffold through a stable triazole linker, enabling dual or synergistic anticancer activity. The disclosed compounds combine the epidermal growth factor receptor (EGFR) inhibitory action of Erlotinib with the pro-apoptotic, antioxidant, and bioactive properties of coumarin derivatives, thereby overcoming limitations associated with conventional therapies, including drug resistance, poor selectivity, and suboptimal pharmacokinetics. The invention further encompassesa scalable and efficient process for the synthesis of the hybrid compounds using copper-catalyzed azide-alkyne cycloaddition (click chemistry), along with purification and characterization methods. Pharmaceutical compositions comprising the said compounds are disclosed, including oral dosage forms such as tablets and capsules, and parenteral formulations such as injectable and lyophilized preparations, formulated with pharmaceutically acceptable excipients. The compounds are useful in the treatment, prevention, and management of various cancers, including hepatocellular carcinoma, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and drugresistant tumors. The invention also provides advantages such as enhanced chemical stability, improved pharmacokinetic and pharmacodynamic profiles, reduced toxicity, and potential theranostic applications due to the intrinsic fluorescence of the coumarin moiety. Overall, the present invention offers a novel and effective platform for the development of next-generation anticancer agents.
Disclaimer: Curated by HT Syndication.
